Platine salt hypersensitivity;Hypersensibilité aux sels de platine

Revue de Pneumologie Clinique

Volumn 64, Issue 1, 2008, Pages 20-26

  Couraud, S ^a,b   Planus, C ^a   Rioufol, C ^a   Mornex, F ^a,b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Adverse effect; Allergy; Drug hypersensitivity; Lung cancer; Platin salt

Indexed keywords

CARBOPLATIN; CISPLATIN; IMMUNOGLOBULIN E; OXALIPLATIN; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ARTICLE; CLINICAL FEATURE; DESENSITIZATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; HUMAN; INCIDENCE; PATCH TEST; PATHOPHYSIOLOGY; PHENOTYPE; PRICK TEST; RISK FACTOR; SKIN MANIFESTATION; SKIN TEST; CHEMICAL STRUCTURE; CHEMISTRY; REVIEW;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; DRUG HYPERSENSITIVITY; HUMANS; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS; RISK FACTORS; SKIN TESTS;

EID: 50949103524     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneumo.2008.06.004     Document Type: Article

References (35)

1. Gernez Y., Barlesi F., Astoul P., and Magnan A. Hypersensibilté au carboplatine: un rôle pour les génériques?. Rev Mal Respir 22 (2005) 8S131-8S136
2. Tourraine F., Sainte Laudy J., Boumediene A., Ndikumwenayo F., Decroisette C., Melloni B., et al. Exploration d'une allergie au sel de platine. Rev Mal Respir 23 (2006) 458-462
3. Pastor M.J. Hypersensibilité aux sels de platine, pharmacovigilance, pneumologie. Rev Mal Respir 23 (2006) 487-488
4. Hunter D., Milton R., and Perry K.M.A. Asthma caused by complex salts of platinum. Br J Ind Med 2 (1945) 92-98
5. Navo M., Kunthur A., Badell M.L., Coffer II L.W., Markman M., Brown J., et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 103 (2006) 608-613
6. Leguy-Seguin V., Jolimoy G., Coudert B., Pernot C., Dalac S., Vabres P., et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allerg Clin Immunol 119 (2007) 726-730
7. Garufi C., Cristaudo A., Vanni B., Bria E., Aschelter A.M., Santucci B., et al. Skin testing and hypersenitivity to oxaliplatin. Ann Oncol 14 (2003) 497-498
8. Siu S.W.K., Chan R.T.T., and Au G.K.H. Hypersensitivity reaction to oxaliplatin: experience of a single institute. Ann Oncol 17 (2006) 259-261
9. Hewitt M.R., and Sun W. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal Cancer 6 (2006) 114-117
10. Dictionnaire Vidal des médicaments, éditions Vidal, Paris, 2007:2 750 p.
11. Gamond D., Bhargava P., and McCormick M.J. Hypersensitivity resactions to oxaliplatin and the application of a desensitization protocol. Oncologist 9 (2004) 546-549
12. Schwartz J.R., Bandera C., Bradley A.M., Brard L., Legare R., Granai C.O., et al. Does the platinum-free interval predict the incidence or severity of hypersensititvity reactions to carboplatin? The experience from Women and Infants'hospital. Gynecol Oncol 105 (2007) 81-83
13. Markman M., Kennedy A., Webster K., Elson P., Peterson G., Kulp B., et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17 (1999) 1141
14. Polyzos A., Tsavaris N., Kosmas C., Arnaouti T., Kalahanis N., Tsigris C., et al. Oncology. 61 (2001) 129-133
15. Newman Taylor A.J., Cullinan P., Lympany P.A., Harris J.M., Dowdeswell R.J., and du Bois R.M. Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salt. Am J Respir Crit Care Med 160 (1999) 435-438
16. Meyer L., Zuberbier T., Worm M., Oettle H., and Riess H. Hypersensitivity reactions to oxaliplatin: Cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 20 (2002) 1146-1147
17. Shepherd G.M. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 24 (2003) 253-262
18. Thomas R.R., Quinn M.G., Schuler B., and Grem J.L. Hypersensitivity and idiosyncrasic reactions to oxaliplatin. Cancer 97 (2003) 2301-2307
19. Bégaud B., Evreux J.C., Jouglard J., and Lagier J. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Thérapie 40 (1985) 111-118
20. Johansson S.G.O., Bieber T., Dahl R., Friedmann P.S., Lanier B.Q., Lockey R.F., et al. Revised nomenclature for allergy for global use: report of the nomenclature review comittee of the world allergy organization, october 2003. J Allergy Clin Immunol 113 (2004) 832-836
21. Herrero T., Tornero P., Infante S., Fuentes V., Sanchez M.N., De Barrio M., et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol 16 (2006) 327-330
22. Hedge V.L., and Venkatesh Y.P. Anaphylaxis to excipient mannitol: evidence for an immunoglobulin E-mediated mechanism. Clin Exp Allergy 34 (2004) 1602-1609
23. Markman M., Zanotti K., Peterson G., Kulp B., Webster K., and Belinson J. Expanded experience with intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 21 (2003) 4611-4614
24. Zanotti K.M., Rybicki L.A., Kennedy A.W., Belinson J.L., Webster K.D., Kulp B., et al. Carboplatin skin testing: a skin testing protocol for predicting hypersensibility to carboplatin chemotherapy. J Clin Oncol 19 (2001) 3126-3129
25. Shukunami K., Kurokawa T., Kubo M., Kaneshima M., Kamitani N., and Kotsuji F. Hypersensitivity reaction to carboplatin during treatment for ovarian cancer: successful resolution by replacement with cisplatin. Tumori 85 (1999) 297-298
26. Porzio G., Marchetti P., Paris I., Narducci F., Ricevuto E., and Ficorella C. Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin. Eur J Gynaecol Oncol 23 (2002) 335-336
27. Ottaiano A., Tambaro R., Greggi S., Prato R., Di Maio M., Esposito G., et al. Safety of cisplatin after severe reaction to carboplatin in patients with recurrent ovarian carcinoma. Anticancer Res 23 (2003) 3465-3468
28. Jones R., Ryan M., and Fiedlander M. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol 89 (2003) 112-115
29. Gutierrez M., Pautier P., and Lhommé C. Replacement of carboplatin by oxaliplatin may be one solution for patient treated for ovarian carcinoma who are hypersensitive to carboplatin. J Clin Oncol 20 (2002) 353-358
30. Meyer L., Zuberbier T., Worm M., Oette H., and Riess H. Hypersensitivity reactions to oxaliplatin: cross reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 14 (2006) 1146-1147
31. Bhargava P., Gammon D., and Mc Cormick M.J. Hypersensitivity and idiosyncrasic reactions to oxaliplatin. Cancer 100 (2004) 211-213
32. Confino-Cohen R., Fishman A., Altaras M., and Goldberg A. Successful carboplatin desensitization in patient with proven carboplatin allergy. Cancer 104 (2005) 640-643
33. Lee C.W., Matulonis U.A., and Castells M.C. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitisations in patients with gynaecological malignancies and mast cell/IgEmediated reactions. Gynecol Oncol 95 (2004) 370-376
34. Morgan M., Bowers D.C., Gruchalla R.S., and Khan D. safety and efficacy of repeated monthly carboplatin desensitization. J Allergy Clin immunol 114 (2004) 974-975
35. Stahl M., Köster W., and Wilke H. Reaction after oxaliplatin - prevention with corticosteroids?. Ann Oncol 12 (2001) 874